Johnson & Johnson has walked away and Sanofi has reportedly taken its place in talks for a deal with Actelion Pharmaceuticals Ltd. that, if consummated, could value the Swiss pulmonary arterial hypertension specialist at up to an eye-watering $30bn.
It was less than two months ago that Sanofi's CEO Olivier Brandicourt said the French group would consider a mid-sized...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

